S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
NASDAQ:KDNY

Chinook Therapeutics (KDNY) Stock Forecast, Price & News

$20.44
+0.07 (+0.34%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$19.77
$21.11
50-Day Range
$15.18
$20.44
52-Week Range
$10.48
$21.11
Volume
673,502 shs
Average Volume
381,671 shs
Market Capitalization
$1.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.00

Chinook Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
81.0% Upside
$37.00 Price Target
Short Interest
Healthy
4.60% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.16mentions of Chinook Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$190,450 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.49) to ($2.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

323rd out of 1,283 stocks

Pharmaceutical Preparations Industry

136th out of 615 stocks

Chinook Therapeutics logo

About Chinook Therapeutics (NASDAQ:KDNY) Stock

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.

Chinook Therapeutics Price Performance

KDNY Stock opened at $20.44 on Friday. The firm has a 50-day simple moving average of $17.97 and a 200-day simple moving average of $15.39. Chinook Therapeutics has a 52 week low of $10.48 and a 52 week high of $21.11.

Chinook Therapeutics (NASDAQ:KDNY - Get Rating) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.14. Chinook Therapeutics had a negative net margin of 180.48% and a negative return on equity of 23.24%. The company had revenue of $2.70 million during the quarter. On average, analysts predict that Chinook Therapeutics will post -2.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

KDNY has been the subject of a number of research reports. Stifel Nicolaus initiated coverage on shares of Chinook Therapeutics in a research note on Monday, June 27th. They set a "buy" rating and a $30.00 target price for the company. SVB Leerink boosted their target price on shares of Chinook Therapeutics from $38.00 to $44.00 and gave the stock an "outperform" rating in a research note on Monday, May 23rd.

Insider Activity at Chinook Therapeutics

In related news, insider Andrew James King sold 5,000 shares of the company's stock in a transaction dated Monday, July 11th. The shares were sold at an average price of $18.09, for a total transaction of $90,450.00. Following the completion of the sale, the insider now owns 5,897 shares of the company's stock, valued at approximately $106,676.73. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 23.38% of the stock is owned by corporate insiders.

Receive KDNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chinook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KDNY Stock News Headlines

Checking Out Chinook Therapeutics
Chinook Therapeutics Presents Data from...
See More Headlines

Receive KDNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chinook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KDNY Company Calendar

Last Earnings
5/12/2022
Today
8/07/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KDNY
Fax
N/A
Employees
138
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$37.00
High Stock Price Forecast
$44.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+81.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-102,940,000.00
Net Margins
-180.48%
Pretax Margin
-172.13%

Debt

Sales & Book Value

Annual Sales
$51.63 million
Book Value
$10.06 per share

Miscellaneous

Free Float
42,277,000
Market Cap
$1.13 billion
Optionable
Optionable
Beta
0.03














KDNY Stock - Frequently Asked Questions

Should I buy or sell Chinook Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chinook Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Chinook Therapeutics stock.
View analyst ratings for Chinook Therapeutics
or view top-rated stocks.

What is Chinook Therapeutics' stock price forecast for 2022?

3 Wall Street analysts have issued 1 year price targets for Chinook Therapeutics' stock. Their KDNY stock forecasts range from $30.00 to $44.00. On average, they anticipate Chinook Therapeutics' share price to reach $37.00 in the next twelve months. This suggests a possible upside of 81.0% from the stock's current price.
View analysts' price targets for Chinook Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Chinook Therapeutics' stock performed in 2022?

Chinook Therapeutics' stock was trading at $16.31 at the start of the year. Since then, KDNY shares have increased by 25.3% and is now trading at $20.44.
View the best growth stocks for 2022 here
.

Are investors shorting Chinook Therapeutics?

Chinook Therapeutics saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 2,540,000 shares, an increase of 25.1% from the June 30th total of 2,030,000 shares. Based on an average daily trading volume, of 660,300 shares, the days-to-cover ratio is currently 3.8 days.
View Chinook Therapeutics' Short Interest
.

When is Chinook Therapeutics' next earnings date?

Chinook Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Chinook Therapeutics
.

How were Chinook Therapeutics' earnings last quarter?

Chinook Therapeutics, Inc. (NASDAQ:KDNY) posted its quarterly earnings data on Thursday, May, 12th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.14. The business earned $2.70 million during the quarter. Chinook Therapeutics had a negative trailing twelve-month return on equity of 23.24% and a negative net margin of 180.48%.

What other stocks do shareholders of Chinook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR).

What is Chinook Therapeutics' stock symbol?

Chinook Therapeutics trades on the NASDAQ under the ticker symbol "KDNY."

Who are Chinook Therapeutics' major shareholders?

Chinook Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (1.92%), Candriam S.C.A. (1.58%), Connor Clark & Lunn Investment Management Ltd. (0.22%), Marquette Asset Management LLC (0.07%), SG Americas Securities LLC (0.04%) and Mirae Asset Global Investments Co. Ltd. (0.02%). Company insiders that own Chinook Therapeutics stock include Alan Glicklich, Andrew James King, Davis Jerel, Eric Bjerkholt, Eric Dobmeier, Srinivas Akkaraju, Tom Frohlich and Versant Venture Capital Vii, L.
View institutional ownership trends for Chinook Therapeutics
.

How do I buy shares of Chinook Therapeutics?

Shares of KDNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chinook Therapeutics' stock price today?

One share of KDNY stock can currently be purchased for approximately $20.44.

How much money does Chinook Therapeutics make?

Chinook Therapeutics (NASDAQ:KDNY) has a market capitalization of $1.13 billion and generates $51.63 million in revenue each year. The company earns $-102,940,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis.

How many employees does Chinook Therapeutics have?

Chinook Therapeutics employs 138 workers across the globe.

How can I contact Chinook Therapeutics?

Chinook Therapeutics' mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The official website for Chinook Therapeutics is chinooktx.com. The company can be reached via phone at (206) 485-7051 or via email at investors@aduro.com.

This page (NASDAQ:KDNY) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.